Markt geöffnet· · EUR · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
PARIS, September 07, 2026--Regulatory News: Mauna Kea Technologies (Paris:ALMKT):
PARIS & BOSTON, August 26, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the publication of a landmark independent systematic review and meta-analysis of probe-based confocal laser endomicroscopy (pCLE) in upper gastrointestinal cancer, conducted and funded by Korea's national health technology assessment agency.
PARIS & BOSTON, July 28, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that two new peer-reviewed studies published across leading gastroenterology journals reinforce the growing body of evidence supporting needle-based confocal laser endomicroscopy (nCLE) for the diagnosis of pancreatic cystic lesions (PCLs).
PARIS & BOSTON, July 21, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reported its sales for the first half of 2026.
PARIS & BOSTON, July 16, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces that it will host a webinar for its shareholders and the financial community on Tuesday, July 21, 2026.
PARIS & BOSTON, July 15, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT) (the "Company"), inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy platform (p/nCLE), today announces the establishment of a shareholder loan agreement with Vester Finance, repayable in cash or in new shares.
PARIS & BOSTON, June 04, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, held its Combined General Meeting of June 4, 2026, which was chaired by Mr. Sacha Loiseau, Chairman of the Board of Directors and CEO.
PARIS & BOSTON, June 03, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today highlighted the publication of a prospective study in the United European Gastroenterology Journal (Minea et al.1) that strengthens the case for Cellvizio as a differentiated tool to predict relapse in ulcerative colitis (UC). The study introduces "triple healing" as a new thera
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.